You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
益方生物(688382.SH):目前國內已有一款進口和兩款國產三代EGFR靶向藥物上市
格隆匯 07-24 08:59

格隆匯7月24日丨益方生物(688382.SH)近期在接待機構投資者調研時表示,目前國內已有一款進口和兩款國產三代EGFR靶向藥物上市,第三代EGFR抑制劑在一線和二線治療展現出顯著療效優勢,從2021、2022年三代EGFR產品銷售數據看,三代對第一代產品呈現出持續替代的趨勢。公司和貝達藥業合作開發的貝福替尼二線適應症已於今年5月獲批上市,一線適應症正在CDE審評中。其臨牀數據有自己的亮點,貝福替尼在非小細胞肺癌一線、二線治療臨牀試驗報導了目前已知最長的PFS數據。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account